Search

Author/Creator Kupcinskas, L

1. DOP019 Immunomodulators reduce the risk of surgery and hospitalisation in Crohn's disease in a prospective European population-based inception cohort: the Epi-IBD cohort. (16th January 2018)

Authors:
Burisch, J; Andersen, V; Čuković-Čavka, S; Lakatos, P L; D'Inca, R; Magro, F; Arebi, N; Kievit, L; Kaimakliotis, I; Valpiani, D; Katsanos, K H; Vegh, Z; Dahlerup, J F; Fumery, M; Pedersen, N; Halfvarson, J; Belousova, E; Nielsen, K R; Turcan, S; Ellul, P
Journal:
Journal of Crohn's and colitis
Issue:
Volume 12:Number 1(2018:Jan.)Supplement 1
Page Start:
S042
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. East–West gradient in the incidence of inflammatory bowel disease in Europe: the ECCO-EpiCom inception cohort. Issue 4 (20th April 2013)

Authors:
Burisch, J; Pedersen, N; Čuković-Čavka, S; Brinar, M; Kaimakliotis, I; Duricova, D; Shonová, O; Vind, I; Avnstrøm, S; Thorsgaard, N; Andersen, V; Krabbe, S; Dahlerup, J F; Salupere, R; Nielsen, K R; Olsen, J; Manninen, P; Collin, P; Tsianos, E V; Katsanos, K H
Journal:
Gut
Issue:
Volume 63:Issue 4(2014)
Page Start:
588
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. OP15 Cost analysis in a prospective European population-based inception cohort: is there a cost-saving effect of biological therapy?. (25th January 2019)

Authors:
Burisch, J; Vardi, H; Schwartz, D; Krznaric, Z; Lakatos, P L; Fumery, M; Kupcinskas, L; Magro, F; Belousova, E; Oksanen, P; Arebi, N; Langholz, E; Turcan, S; D'Inca, R; Hernandez, V; Valpiani, D; Vegh, Z; Giannotta, M; Katsanos, K H; Duricova, D
Journal:
Journal of Crohn's and colitis
Issue:
Volume 13(2019)Supplement 1
Page Start:
S009
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. P778 Effectiveness and safety of a second-line rescue therapy for acute severe ulcerative colitis refractory to infliximab or ciclosporin (REASUC study). (30th January 2023)

Authors:
García, M J; Riestra, S; Amiot, A; Julsgaard, M; García de la Filia, I; Calafat, M; Aguas, M; de la Peña, L; Roig-Ramos, C; Caballol, B; Casanova, M J; Farkas, K; Boysen, T; Bujanda, L; Cuarán, C; Dobru, D; Fousekis, F; Gargallo-Puyuelo, C J; Savarino, E; Calvet, X
Journal:
Journal of Crohn's and colitis
Issue:
Volume 17(2023)Supplement 1
Page Start:
i911
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. P812 Natural disease course of inflammatory bowel disease unclassified in a prospective European population-based inception cohort—the Epi-IBD cohort. (16th January 2018)

Authors:
Burisch, J; Ellul, P; Arebi, N; Kaimakliotis, I; D'Inca, R; Andersen, V; Belousova, E; Hernandez, V; Vegh, Z; Turcan, S; Magro, F; Kupcinskas, L; Halfvarson, J; Lakatos, P L; Duricova, D; Kievit, L; Goldis, A; Dahlerup, J F; Oksanen, P; Čuković-Čavka, S
Journal:
Journal of Crohn's and colitis
Issue:
Volume 12:Number 1(2018:Jan.)Supplement 1
Page Start:
S523
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗